Skip to main content
SpringerLink
Log in

Cardiac Biomarkers by Point-of-Care Testing

  • Chapter
Cardiovascular Biomarkers

Part of the book series: Contemporary Cardiology ((CONCARD))

Abstract

Point-of-care (POC) testing offers the opportunity to provide more rapid measurement of cardiac biomarkers in the environment in which clinical decisions about patient management are made. The technology of POC testing utilizes whole blood to measure one or more analytes including cardiac biomarkers such as creatine kinase-MB isoenzyme, myoglobin, cardiac troponins T and I, and B-type natriuretic peptide. Measurement methods include immunochromatographic separation usually combined with a quantitative reader, dedicated heterogeneous immunoassay systems, and those suitable for POC and emergency laboratory testing. Analytic performance of these systems approaches but does not always equal those of conventional laboratory methods. Evaluation of POC testing of cardiac biomarker measurement has shown good analytic and clinical diagnostic performance. These systems are entirely suitable for rule-in diagnosis of myocardial infarction (MI). Although POC testing has also been shown to be suitable for rule-out strategies, there is a lack of studies comparing POC testing with laboratory measurements for diagnosis using updated criteria for acute MI or for prognosis. Although POC testing is faster, there is only limited evidence that the speed and convenience of these systems can have a direct impact on outcome measures such as treatment selection or length of stay. More work is needed in this area.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996;94(8):2013–2020.

    PubMed  CAS  Google Scholar 

  2. Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986;73(3):418–427.

    PubMed  CAS  Google Scholar 

  3. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985;71(4):699–708.

    PubMed  CAS  Google Scholar 

  4. Wu AH, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes R Jr. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem 1999;45(7):1104–1121.

    PubMed  CAS  Google Scholar 

  5. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/ American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000;21(18):1502–1513.

    Google Scholar 

  6. Collinson PO, Boa FG, Gaze DC. Measurement of cardiac troponins. Ann Clin Biochem 2001;38(Pt 5): 423–449.

    Article  PubMed  CAS  Google Scholar 

  7. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004;110(5): 588–636.

    Article  PubMed  Google Scholar 

  8. Stubbs P, Collinson P, Moseley D, Greenwood T, Noble M. Prognostic significance of admission troponin T concentrations in patients with myocardial infarction. Circulation 1996;94(6):1291–1297.

    PubMed  CAS  Google Scholar 

  9. Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators [see comments]. N Engl J Med 1996;335(18): 1333–1341.

    Article  PubMed  CAS  Google Scholar 

  10. Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003;107(22):2786–2792.

    Article  PubMed  CAS  Google Scholar 

  11. Galvani M, Ottani F, Oltrona L, et al. N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation 2004;110(2):128–134.

    Article  PubMed  CAS  Google Scholar 

  12. Mega JL, Morrow DA, de Lemos JA, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol 2004;44(2):335–339.

    Article  PubMed  CAS  Google Scholar 

  13. Collinson PO, Rao AC, Canepa-Anson R, Joseph S. Impact of European Society of Cardiology/American College of Cardiology guidelines on diagnostic classification of patients with suspected acute coronary syndromes. Ann Clin Biochem 2003;40(Pt 2):156–160.

    Article  PubMed  CAS  Google Scholar 

  14. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002;23(23):1809–1840.

    Article  PubMed  Google Scholar 

  15. Collinson PO. The need for a point of care testing: an evidence-based appraisal. Scand J Clin Lab Invest Suppl 1999;230:67–73.

    PubMed  CAS  Google Scholar 

  16. McCord J, Nowak RM, McCullough PA, et al. Ninety-minute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin I. Circulation 2001;104(13):1483–1488.

    Article  PubMed  CAS  Google Scholar 

  17. Kilgore ML, Steindel SJ, Smith JA. Evaluating stat testing options in an academic health center: therapeutic turnaround time and staff satisfaction. Clin Chem 1998;44(8 Pt 1):1597–1603.

    PubMed  CAS  Google Scholar 

  18. Gibler WB, Runyon JP, Levy RC, et al. A rapid diagnostic and treatment center for patients with chest pain in the emergency department [see comments]. Ann Emerg Med 1995;25(1):1–8.

    Article  PubMed  CAS  Google Scholar 

  19. Gibler WB. Evaluating patients with chest pain in the ED: improving speed, efficiency, and cost-effectiveness, or teaching an old dog new tricks [editorial; comment]. Ann Emerg Med 1994;23(2):381, 382.

    Article  PubMed  CAS  Google Scholar 

  20. Goodacre SW, Morris FM, Campbell S, Arnold J, Angelini K. A prospective, observational study of a chest pain observation unit in a British hospital. Emerg Med J 2002;19(2):117–121.

    Article  PubMed  CAS  Google Scholar 

  21. Gomez MA, Anderson JL, Karagounis LA, Muhlestein JB, Mooers FB. An emergency department-based protocol for rapidly ruling out myocardial ischemia reduces hospital time and expense: results of a randomized study (ROMIO). J Am Coll Cardiol 1996;28(1):25–33.

    Article  PubMed  CAS  Google Scholar 

  22. Goodacre S, Nicholl J, Dixon S, et al. Randomised controlled trial and economic evaluation of a chest pain observation unit compared with routine care. BMJ 2004;328(7434):254–260.

    Article  PubMed  Google Scholar 

  23. Collinson PO, Ramhamadamy EM, Stubbs PJ, et al. Rapid enzyme diagnosis of patients with acute chest pain reduces patient stay in the coronary care unit. Ann Clin Biochem 1993;30(Pt 1):17–22.

    PubMed  Google Scholar 

  24. Apple FS, Preese LM, Riley L, Gerken KL, Van Lente F. Financial impact of a rapid CK-MB-specific immunoassay on the diagnosis of myocardial infarction. Arch Pathol Lab Med 1990;114(10):1017–1020.

    PubMed  CAS  Google Scholar 

  25. Wu AH, Clive JM. Impact of CK-MB testing policies on hospital length of stay and laboratory costs for patients with myocardial infarction or chest pain [see comments]. Clin Chem 1997;43(2):326–332.

    PubMed  CAS  Google Scholar 

  26. Lee-Lewandrowski E, Corboy D, Lewandrowski K, Sinclair J, McDermot S, Benzer TI. Implementation of a point-of-care satellite laboratory in the emergency department of an academic medical center: impact on test turnaround time and patient emergency department length of stay. Arch Pathol Lab Med 2003;127(4):456–460.

    PubMed  Google Scholar 

  27. Hirschl MM, Lechleitner P, Friedrich G, et al. Usefulness of a new rapid bedside troponin T assay in patients with chest pain. Resuscitation 1996;32(3):193–198.

    Article  PubMed  CAS  Google Scholar 

  28. Evaluation of a bedside whole-blood rapid troponin T assay in the emergency department. Rapid Evaluation by Assay of Cardiac Troponin T (REACTT) Investigators Study Group. Acad Emerg Med 1997;4(11):1018–1024.

    Google Scholar 

  29. Schwartz JG, Gage CL, Farley NJ, Prihoda TJ. Evaluation of the cardiac STATus CK-MB/myoglobin card test to diagnose acute myocardial infarctions in the ED. Am J Emerg Med 1997;15(3):303–307.

    Article  PubMed  CAS  Google Scholar 

  30. Schouten Y, de Winter RJ, Gorgels JP, Koster RW, Adams R, Sanders GT. Clinical evaluation of the CARDIAC STATus, a rapid immunochromatographic assay for simultaneous detection of elevated concentrations of CK-MB and myoglobin in whole blood. Clin Chem Lab Med 1998;36(7):469–473.

    Article  PubMed  CAS  Google Scholar 

  31. Brogan GX Jr, Bock JL, McCuskey CF, et al. Evaluation of cardiac STATus CK-MB/myoglobin device for rapidly ruling out acute myocardial infarction. Clin Lab Med 1997;17(4):655–668.

    PubMed  Google Scholar 

  32. Panteghini M, Cuccia C, Pagani F, Turla C. Comparison of the diagnostic performance of two rapid bedside biochemical assays in the early detection of acute myocardial infarction. Clin Cardiol 1998;21(6):394–398.

    Article  PubMed  CAS  Google Scholar 

  33. Luscher MS, Ravkilde J, Thygesen K. Clinical application of two novel rapid bedside tests for the detection of cardiac troponin T and creatine kinase-MB mass/myoglobin in whole blood in acute myocardial infarction. Cardiology 1998;89(3):222–228.

    Article  PubMed  CAS  Google Scholar 

  34. Sylven C, Lindahl S, Hellkvist K, Nyquist O, Rasmanis G. Excellent reliability of nurse-based bedside diagnosis of acute myocardial infarction by rapid dry-strip creatine kinase MB, myoglobin, and troponin T. Am Heart J 1998;135(4):677–683.

    Article  PubMed  CAS  Google Scholar 

  35. Muller-Bardorff M, Rauscher T, Kampmann M, et al. Quantitative bedside assay for cardiac troponin T: a complementary method to centralized laboratory testing. Clin Chem 1999;45(7):1002–1008.

    PubMed  CAS  Google Scholar 

  36. Collinson PO, Jorgensen B, Sylven C, et al. Recalibration of the point-of-care test for CARDIAC T Quantitative with Elecsys Troponin T 3rd generation. Clin Chim Acta 2001;307(1–2):197–203.

    Article  PubMed  CAS  Google Scholar 

  37. Muller-Bardorff M, Sylven C, Rasmanis G, et al. Evaluation of a point-of-care system for quantitative determination of troponin T and myoglobin. Clin Chem Lab Med 2000;38(6):567–574.

    Article  PubMed  CAS  Google Scholar 

  38. Apple FS, Christenson RH, Valdes R Jr, et al. Simultaneous rapid measurement of whole blood myoglobin, creatine kinase MB, and cardiac troponin I by the triage cardiac panel for detection of myocardial infarction. Clin Chem 1999;45(2):199–205.

    PubMed  CAS  Google Scholar 

  39. Altinier S, Mion M, Cappelletti A, Zaninotto M, Plebani M. Rapid measurement of cardiac markers on Stratus CS. Clin Chem 2000;46(7):991–993.

    PubMed  CAS  Google Scholar 

  40. Heller GV, Blaustein AS, Wei JY. Implications of increased myocardial isoenzyme level in the presence of normal serum creatine kinase activity. Am J Cardiol 1983;51(1):24–27.

    Google Scholar 

  41. Clyne CA, Medeiros LJ, Marton KI. The prognostic significance of immunoradiometric CK-MB assay (IRMA) diagnosis of myocardial infarction in patients with low total CK and elevated MB isoenzymes. Am Heart J 1989;118(5 Pt 1):901–906.

    Google Scholar 

  42. Antman EM, Sacks DB, Rifai N, McCabe CH, Cannon CP, Braunwald E. Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy. J Am Coll Cardiol 1998;31(2):326–330.

    Article  PubMed  CAS  Google Scholar 

  43. Ohman EM, Armstrong PW, White HD, et al. Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. Am J Cardiol 1999;84(11):1281–1286.

    Article  PubMed  CAS  Google Scholar 

  44. Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med 1997;337(23):1648–1653.

    Article  PubMed  CAS  Google Scholar 

  45. Heeschen C, Goldmann BU, Langenbrink L, Matschuck G, Hamm CW. Evaluation of a rapid whole blood ELISA for quantification of troponin I in patients with acute chest pain. Clin Chem 1999;45(10): 1789–1796.

    PubMed  CAS  Google Scholar 

  46. Newby LK, Storrow AB, Gibler WB, et al. Bedside multimarker testing for risk stratification in chest pain units: the Chest Pain Evaluation by Creatine Kinase-MB, Myoglobin, and Troponin I (CHECKMATE) study. Circulation 2001;103(14):1832–1837.

    PubMed  CAS  Google Scholar 

  47. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation 1979;59(3):607–609.

    Google Scholar 

  48. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000;21(18):1502–1513.

    Google Scholar 

  49. Downie AC, Frost PG, Fielden P, Joshi D, Dancy CM. Bedside measurement of creatine kinase to guide thrombolysis on the coronary care unit. Lancet 1993;341(8843):452–454.

    Article  PubMed  CAS  Google Scholar 

  50. Gibler WB, Hoekstra JW, Weaver WD, et al. A randomized trial of the effects of early cardiac serum marker availability on reperfusion therapy in patients with acute myocardial infarction: the Serial Markers, Acute Myocardial Infarction and Rapid Treatment Trial (SMARTT). J Am Coll Cardiol 2000;36(5): 1500–1506.

    Article  PubMed  CAS  Google Scholar 

  51. Young GP, Gibler WB, Hedges JR, et al. Serial creatine kinase-MB results are a sensitive indicator of acute myocardial infarction in chest pain patients with nondiagnostic electrocardiograms: the second Emergency Medicine Cardiac Research Group Study. Acad Emerg Med 1997;4(9):869–877.

    Article  PubMed  CAS  Google Scholar 

  52. Hedges JR, Gibler WB, Young GP, et al. Multicenter study of creatine kinase-MB use: effect on chest pain clinical decision making. Acad Emerg Med 1996;3(1):7–15.

    Article  PubMed  CAS  Google Scholar 

  53. Hedges JR, Young GP, Henkel GF, Gibler WB, Green TR, Swanson JR. Early CK-MB elevations predict ischemic events in stable chest pain patients. Acad Emerg Med 1994;1(1):9–16.

    Article  PubMed  CAS  Google Scholar 

  54. Hoekstra JW, Hedges JR, Gibler WB, Rubison RM, Christensen RA. Emergency department CK-MB: a predictor of ischemic complications. National cooperative CK-MB project group. Acad Emerg Med 1994;1(1):17–27.

    Article  PubMed  CAS  Google Scholar 

  55. Hedges JR, Young GP, Henkel GF, Gibler WB, Green TR, Swanson JR. Serial ECGs are less accurate than serial CK-MB results for emergency department diagnosis of myocardial infarction. Ann Emerg Med 1992;21(12):1445–1450.

    Article  PubMed  CAS  Google Scholar 

  56. Ng SM, Krishnaswamy P, Morissey R, Clopton P, Fitzgerald R, Maisel AS. Ninety-minute accelerated critical pathway for chest pain evaluation. Am J Cardiol 2001;88(6):611–617.

    Article  PubMed  CAS  Google Scholar 

  57. Panteghini M, Pagani F, Yeo KT, et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem 2004;50(2):327–332.

    Article  PubMed  CAS  Google Scholar 

  58. Morrow DA, Rifai N, Sabatine MS, et al. Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes. Clin Chem 2003;49(8):1396–1398.

    Article  PubMed  CAS  Google Scholar 

  59. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344(25):1879–1887.

    Article  PubMed  CAS  Google Scholar 

  60. Sayre MR, Kaufmann KH, Chen IW, et al. Measurement of cardiac troponin T is an effective method for predicting complications among emergency department patients with chest pain [see comments]. Ann Emerg Med 1998;31(5):539–549.

    Article  PubMed  CAS  Google Scholar 

  61. Fuchs S, Kornowski R, Mehran R, et al. Cardiac troponin I levels and clinical outcomes in patients with acute coronary syndromes: the potential role of early percutaneous revascularization. J Am Coll Cardiol 1999;34(6):1704–1710.

    Article  PubMed  CAS  Google Scholar 

  62. Johnson PA, Goldman L, Sacks DB, et al. Cardiac troponin T as a marker for myocardial ischemia in patients seen at the emergency department for acute chest pain. Am Heart J 1999;137(6):1137–1144.

    Article  PubMed  CAS  Google Scholar 

  63. Kontos MC, Shah R, Fritz LM, et al. Implication of different cardiac troponin I levels for clinical outcomes and prognosis of acute chest pain patients. J Am Coll Cardiol 2004;43(6):958–965.

    Article  PubMed  CAS  Google Scholar 

  64. Collinson PO, Stubbs PJ. Are troponins confusing? Heart 2003;89(11):1285–1287.

    CAS  Google Scholar 

  65. Kendall J, Reeves B, Clancy M. Point of care testing: randomised controlled trial of clinical outcome. BMJ 1998;316(7137):1052–1057.

    PubMed  CAS  Google Scholar 

  66. Parvin CA, Lo SF, Deuser SM, Weaver LG, Lewis LM, Scott MG. Impact of point-of-care testing on patients’ length of stay in a large emergency department. Clin Chem 1996;42(5):711–717.

    PubMed  CAS  Google Scholar 

  67. Collinson PO, John CM, Lynch S, et al. A prospective randomised control trial of point of care testing on the coronary care unit. Ann Clin Biochem 2004;40:41:397–404.

    Article  Google Scholar 

  68. Hobbs FD, Davis RC, Roalfe AK, Hare R, Davies MK, Kenkre JE. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ 2002;324(7352):1498–1503.

    Article  PubMed  CAS  Google Scholar 

  69. Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 2004;90(3):297–303.

    Article  PubMed  CAS  Google Scholar 

  70. Hobbs FD, Davis RC, Roalfe AK, Hare R, Davies MK. Reliability of N-terminal proBNP assay in diagnosis of left ventricular systolic dysfunction within representative and high risk populations. Heart 2004;90(8):866–870.

    Article  PubMed  CAS  Google Scholar 

  71. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002;40(3):437–445.

    Article  PubMed  CAS  Google Scholar 

  72. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345(14):1014–1021.

    Article  PubMed  Google Scholar 

  73. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347(3):161–167.

    Article  PubMed  CAS  Google Scholar 

  74. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001;37(2): 386–391.

    Article  PubMed  CAS  Google Scholar 

  75. Wu AH, Packer M, Smith A, et al. Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. Clin Chem 2004;50(5):867–873.

    Article  PubMed  CAS  Google Scholar 

  76. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350(7):647–654.

    Article  PubMed  CAS  Google Scholar 

  77. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107(9):1278–1283.

    Article  PubMed  CAS  Google Scholar 

  78. Latini R, Masson S, Anand I, et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002;106(19):2454–2458.

    Article  PubMed  CAS  Google Scholar 

  79. Richards AM, Doughty R, Nicholls MG, et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation 1999;99(6): 786–792.

    PubMed  CAS  Google Scholar 

  80. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355(9210):1126–1130.

    Article  PubMed  CAS  Google Scholar 

  81. Anon. Seynge of Urynes. R. Kele, London, 1552.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chemical Pathology, St George’s Hospital, London, UK

    Paul O. Collinson MD, FRCPath, FACB (Director of Pathology and Consultant in Chemical Pathology)

Authors
  1. Paul O. Collinson MD, FRCPath, FACB
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

    David A. Morrow MD, MPH

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Collinson, P.O. (2006). Cardiac Biomarkers by Point-of-Care Testing. In: Morrow, D.A. (eds) Cardiovascular Biomarkers. Contemporary Cardiology. Humana Press. https://doi.org/10.1007/978-1-59745-051-5_32

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-051-5_32

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-526-2

  • Online ISBN: 978-1-59745-051-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation